Philippe Aftimos

Department : Medical oncology , Clinical Trials Conduct Unit (CTCU)

philippe.aftimos [at] hubruxelles.be

Publications

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.

Authors : Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA
Year : 2023
Journal : JAMA Oncol

Liquid biopsy accelerates precision medicine.

Authors : Amato O, Aftimos P, Ignatiadis M
Year : 2023
Journal : Ann Oncol

[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.

Authors : Iqbal R, Yaqub M, Bektas HO, Oprea-Lager DE, de Vries EGE, Glaudemans AWJM, Aftimos P, Gebhart G, Beelen AP, Schuit RC, Windhorst AD, Boellaard R, Menke-van der Houven van Oordt CW
Year : 2023
Journal : Clin Cancer Res

PIK3CA copy number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer.

Authors : Amato O, Buisseret L, Gebhart G, Plouznikoff N, Larsimont D, Awada A, Piccart M, Aftimos P
Year : 2023
Journal : Cold Spring Harb Mol Case Stud

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer.

Authors : Awada AH, Boni V, Moreno V, Aftimos P, Kahatt C, Luepke-Estefan XE, Siguero M, Fernandez-Teruel C, Cullell-Young M, Tabernero J
Year : 2022
Journal : ESMO Open

More publications »

Philippe Aftimos

Languages

Contact